Expression of the Lipid Transporters ABCA3 and ABCA1 is Diminished in Human Breast Cancer Tissue

Abstract

ATP-binding cassette transporters ABCA3 and ABCA1 are related to a differentiated, lipid-secreting phenotype of type II pneumocytes. Since mammary gland epithelial cells also show pronounced lipid metabolism and secretion, we investigated the expression of these proteins in normal as well as in neoplastic breast tissue. Normal human breast tissue, breast cancer cell lines, and 162 tumor samples of patients with primary unilateral invasive breast cancer were analyzed for ABCA3 and ABCA1 protein expression by immunohistochemistry using tissue microarrays. Strong ABCA3 and ABCA1 expression was found in the inner layer of normal mammary gland epithelium. Concurrent cytoplasmic ABCA3 and ABCA1 immunoreactivity was found in 9 of 11 breast cancer cell lines. ABCA3 and ABCA1 were shown to be differentially expressed in human breast cancer. Loss of ABCA3 staining was significantly associated with positive nodal status and negative progesterone receptor expression. In multivariate analysis, diminished ABCA3 expression proved to be a significant, independent and adverse risk factor for tumor recurrence. ABCA1 expression was associated with positive lymph nodes, but not significantly associated with tumor recurrence or breast cancer-specific survival. ABCA3 and ABCA1 are strongly expressed in normal mammary gland epithelium. Decreased ABCA3 expression in breast cancer seems to be associated with poor prognosis.

Key words

estrogen receptors - lipid metabolism - ATP-binding cassette transporters - breast cancer - mammary glands human

References

• 1 MacManaman JL, Neville MC. Mammary physiology and milk secretion.  Adv Drug Deliv Rev. 2003;  55 629-641
• 2 Ban N, Matsumura Y, Sakai H, Takanezawa Y, Sasaki M, Arai H, Inagaki N. ABCA3 as a lipid transporter in pulmonary surfactant biogenesis.  J Biol Chem. 2007;  282 9628-9634
• 3 Brasch F, Schimanski S, Muhlfeld C, Barlage S, Langmann T, Aslanidis C, Boettcher A, Dada A, Schroten H, Mildenberger E, Prueter E, Ballmann M, Ochs M, Johnen G, Griese M, Schmitz G. Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency.  Am J Respir Crit Care Med. 2006;  174 571-580
• 4 Cheong N, Zhang H, Madesh M, Zhao M, Yu K, Dodia C, Fisher AB, Savani RC, Shuman H. ABCA3 is critical for lamellar body biogenesis in vivo.  J Biol Chem. 2007;  282 23811-23817
• 5 Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency.  N Engl J Med. 2004;  350 1296-1303
• 6 Yamano G, Funahashi H, Kawanami O, Zhao LX, Ban N, Uchida Y, Morohoshi T, Ogawa J, Shioda S, Inagaki N. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells.  FEBS Lett. 2001;  508 221-225
• 7 Stahlman MT, Besnard V, Wert SE, Weaver TE, Dingle S, Xu Y, von Zychlin K, Olson SJ, Whitsett JA. Expression of ABCA3 in developing lung and other tissues.  J Histochem Cytochem. 2007;  55 71-83
• 8 Bruder E, Hofmeister J, Aslanidis C, Hammer J, Bubendorf L, Schmitz G, Rufle A, Buhrer C. Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3 mutation.  Mod Pathol. 2007;  20 1009-1018
• 9 Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay.  CAP Today. 1998;  12 1, 14–1, 16 
• 10 Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Durst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.  Clin Cancer Res. 2006;  12 3950-3960
• 11 Kasper G, Weiser AA, Rump A, Sparbier K, Dahl E, Hartmann A, Wild P, Schwidetzky U, Castanos-Velez E, Lehmann K. Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients.  Int J Cancer. 2005;  117 961-973
• 12 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.  Histopathology. 1991;  19 403-410
• 13 Fortunato D, Giuffrida MG, Cavaletto M, Garoffo LP, Dellavalle G, Napolitano L, Giunta C, Fabris C, Bertino E, Coscia A, Conti A. Structural proteome of human colostral fat globule membrane proteins.  Proteomics. 2003;  3 897-905
• 14 Sala-Vila A, Castellote AI, Rodriguez-Palmero M, Campoy C, Lopez-Sabater MC. Lipid composition in human breast milk from Granada (Spain): changes during lactation.  Nutrition. 2005;  21 467-473
• 15 Struck J, de Almeida P, Bergmann A, Morgenthaler NG. High concentrations of procalcitonin but not mature calcitonin in normal human milk.  Horm Metab Res. 2002;  34 460-465
• 16 Zhou J, You Y, Ryan AJ, Mallampalli RK. Upregulation of surfactant synthesis triggers ABCA1-mediated basolateral phospholipid efflux.  J Lipid Res. 2004;  45 1758-1767
• 17 van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer.  Nature. 2002;  415 530-536
• 18 Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets.  Proc Natl Acad Sci USA. 2003;  100 8418-8423
• 19 van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer.  N Engl J Med. 2002;  347 1999-2009
• 20 Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D. Gene expression profiling and clinical outcome in breast cancer.  OMICS. 2006;  10 429-443
• 21 Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT. Gene expression predictors of breast cancer outcomes.  Lancet. 2003;  361 1590-1596
• 22 Van Laere SJ, Van den Eynden GG, Van dA, I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.  Breast Cancer Res Treat. 2006;  95 243-255
• 23 Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours.  Nature. 2000;  406 747-752
• 24 Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.  Proc Natl Acad Sci USA. 2001;  98 10869-10874
• 25 Hernandez P, Sole X, Valls J, Moreno V, Capella G, Urruticoechea A, Pujana MA. Integrative analysis of a cancer somatic mutome.  Mol Cancer. 2007;  6 13
• 26 Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Molecular response to aromatase inhibitor treatment in primary breast cancer.  Breast Cancer Res. 2007;  9 R37
• 27 Perou CM, Jeffrey SS, van de RM, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.  Proc Natl Acad Sci USA. 1999;  96 9212-9217
• 28 Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.  Br J Cancer. 1999;  79 1564-1571
• 29 Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.  J Clin Oncol. 2005;  23 7721-7735
• 30 Gross GE, Clark GM, Chamness GC, McGuire WL. Multiple progesterone receptor assays in human breast cancer.  Cancer Res. 1984;  44 836-840
• 31 Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Fernö M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.  Cancer Res. 2001;  61 5979-5984
• 32 Schmitz G, Niemann R, Brennhausen B, Krause R, Assmann G. Regulation of high density lipoprotein receptors in cultured macrophages. role of acyl-CoA:cholesterol acyltransferase.  EMBO J. 1985;  4 2773-2779

1 S. Schimanski and P. J. Wild contributed equally to this manuscript.

Correspondence